Annexon, Inc.
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
ANNX | US
Overview
Corporate Details
- ISIN(s):
- US03589W1027
- LEI:
- Country:
- United States of America
- Address:
- 1400 SIERRA POINT PARKWAY, 94005 BRISBANE
- Website:
- https://annexonbio.com/
- Sector:
- Manufacturing
Description
Annexon, Inc. is a clinical-stage biopharmaceutical company developing a new class of complement medicines. The company's therapeutic approach is centered on inhibiting C1q, the initiating molecule of the classical complement pathway. By blocking C1q at the start of this immune cascade, Annexon aims to prevent the inflammation and tissue damage that drive a range of diseases. Its pipeline is focused on developing treatments for classical complement-mediated disorders affecting the body, brain, and eye, which include autoimmune, neurodegenerative, and ophthalmic conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Annexon, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Annexon, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Annexon, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
